Glucotrack (GCTK) EBIT (2010 - 2025)

Glucotrack has disclosed EBIT across 15 years of filings, most recently posting -$3.5 million for Q4 2025.

• Quarterly EBIT rose 9.52% year-over-year to -$3.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$16.1 million (down 10.61% YoY) and the FY2025 annual result came in at -$16.1 million, down 10.61% from the prior year.
• EBIT rose to -$3.5 million in Q4 2025, from -$4.3 million in the prior quarter.
• Over five years, EBIT peaked at -$767000.0 in Q3 2021 and troughed at -$4.8 million in Q2 2025.
• A 5-year average of -$2.3 million and a median of -$1.9 million in 2021 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT advanced 14.43% — and 2024, when it tumbled 280.92%.
• Tracing GCTK's EBIT over 5 years: stood at -$1.5 million in 2021, then increased by 14.43% to -$1.3 million in 2022, then sank by 87.8% to -$2.4 million in 2023, then sank by 59.45% to -$3.9 million in 2024, then rose by 9.52% to -$3.5 million in 2025.
• Business Quant data shows GCTK's EBIT at -$3.5 million in Q4 2025, -$4.3 million in Q3 2025, and -$4.8 million in Q2 2025.